Determination of Urinary Myo-/Chiro-Inositol Ratios from Korean Diabetes Patients by Jung, Tae-Sik et al.
Yonsei Medical Journal
Vol. 46, No. 4, pp. 532 - 538, 2005
Yonsei Med J Vol. 46, No. 4, 2005
Of two major forms (myo- and chiro-inositol) of inositols,
only chiro-inositol enhances the activity of proteins involved
in intracellular glucose metabolism. This study aims to
determine the urinary myo-/chiro-inositol ratio in type 1 and
type 2 diabetes patients and compare its ratio with the normal
control group. The 24-hour urinary myo- and chiro-inositols in
71 Korean diabetes patients and 39 control subjects have been
quantified using high-performance liquid chromatography, and
their ratios have been evaluated as indices of insulin resis-
tance. The level of 24-hour urinary myo-inositol was signifi-
cantly higher in both type 1 and type 2 diabetes than with the
control group, whereas the urinary chiro-inositol in type 1 or
type 2 diabetes was lower than that in normal subjects. The
myo-/chiro-inositol ratio in diabetes patients was higher than
that in the control group. Twenty four-hour urinary myo-/
chiro-inositol ratios were significantly elevated in type 1 and
type 2 diabetes patients compared to the control group,
suggesting that a high ratio of urinary myo-/chiro- inositol in
type 2 diabetes patients might be used for an index of insulin
resistance.
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INTRODUCTION
The main pathophysiologic mechanism of type
2 diabetes mellitus is the insulin resistance,
resulting from defects in receptor binding or the
post-receptor signaling pathway during the insu-
lin action. Therefore, a major strategy for treat-
ment of type 2 diabetes focuses on how to over-
come this insulin resistance. Currently, the preva-
lence of type 2 diabetes is rapidly increasing, and
reaches approximately 10% of the world's popula-
tion. Many studies assessed the severity of insulin
resistance and investigated its mechanism. When
insulin binds to its receptor, it activates phos-
pholipase C to hydrolyze phosphatidylinositols,
attached to the cell membranes, to inositols and
diacylglycerols that act as secondary messengers
or mediators in the insulin action.
1-3
Inositols could be directly obtained from inosi-
tol-rich foods or synthesized in the body. More-
over, they exist as two major forms: chiro-inositols
and myo-inositols. Chiro- and myo-inositols have
the same schematic structure except for the con-
figuration of one hydroxyl group at the carbon 1
site (Fig. 1).
4-6 Most inositols exist as myo-inositols
in the body, and myo-inositols are then converted
to chiro-inositols by the insulin action in insulin-
sensitive tissues (muscle, liver, adipose tissues
etc). Therefore, the level of the chiro-inositols in
those tissues can be used for the biomarker of
insulin action.
Chiro-inositol activates pyruvate dehydrogen-
ase phosphatase and glycogen synthase, which are
rate-limiting enzymes during the insulin-medi-
ated glucose metabolism. When chiro-inositols in-
crease in the body, the glucose metabolism is then
elevated by the activated pyruvate dehydro-
genase phosphatase and glycogen synthase. As a
result, the overall insulin reaction is accelerated in
Determination of Urinary Myo-/Chiro-Inositol Ratios from
Korean Diabetes Patients
Tae-Sik Jung,
1 Jong-Ryeal Hahm,
1,4 Jong-Jin Kim,
3 Jung-Hwa Jung,
1 Mi-Yeon Kang,
1 Sung-Won Moon,
1
Kang-Wan Lee,
1 Ho-Cheol Kim,
1,4 Jong-Deog Lee,
1,4 Ji-Hye Kim,
2 Deok-Ryong Kim,
2,4 and Soon-Il Chung
1,4
Departments of
1Internal Medicine,
2Biochemistry, and
3Microbiology, College of Natural Sciences, Gyeongsang National
University, Jinju, Korea;
4Gyeongsang Institute of Health Science, Jinju, Korea.
Received January 19, 2005
Accepted June 1, 2005
This work was supported by the Korea Research Foundation
Grant (KRF-2004-005-E00063).
Reprint address: requests to Dr. Jong Ryeal Hahm, Department
of Internal Medicine, Gyeongsang National University, Jinju 660-
702, Korea. Tel: 82-55-750-8736, Fax: 82-55-758-9122, E-mail:
jrhahm@gshp.gsnu.ac.krDetermination of Urinary Myo-/Chiro-Inositol Ratios from Korean Diabetes Patients
Yonsei Med J Vol. 46, No. 4, 2005
insulin-sensitive tissues.
4-8 Kennington et al.
5 dem-
onstrated that levels of myo-inositols and chiro-
inositols in the muscles and liver are correlated
with those in urine and serum. Thus, the urinary
levels of myo-inositols and chiro-inositols can be
found in other tissues. According to recent studies,
plasma, urinary and muscular chiro-inositol levels
in type 2 diabetes patients were lower than those
in non-diabetic patients.
5 It has also been reported
that chiro-inositol levels were greatly decreased in
the first relatives of patients with type 2 diabetes
or in the non-diabetes insulin resistant group.
9 In
this study we determined the level of myo-ino-
sitols and chiro-inositols in the 24-hour urine sam-
ple of type 1 and type 2 diabetes or the control
group to examine that the myo-/chiro-inositol ratio
is elevated in patients with type 1 and type 2
diabetes mellitus more than the control.
MATERIALS AND METHODS
Subjects
Participants in this study included 77 diabetes
patients (12 type 1 diabetes patients, 65 type 2
diabetes patients) and 39 control subjects. They
visited Gyeongsang National University Hospital
as outpatients or inpatients between April and
September of 2002. We explained our study to
them and received written consent from all par-
ticipants. Patients were excluded if any of the
following circumstances were present: age less
than 20 or over 70 years; severe vascular compli-
cations such as coronary artery disease, cerebro-
vascular disease, or peripheral vascular disease;
creatinine clearance was less than 60 mL/kg/min;
malignancy or severe illness such as liver cir-
rhosis, congestive heart failure, chronic obstruc-
tive lung disease; drug use within 4 weeks that
would influence inositol metabolism such as
vitamin B complex, anticonvulsants, or herbal
medications; severe mental retardation or psy-
chiatric disorders; infection within the last two
weeks; malnutrition; pregnancy and abnormal
hemoglobin, white blood cell count, or platelet
count; serum aspartate transferase, alanine trans-
ferase or cholesterol level. Among the 77 subjects,
six patients were excluded, because they either
failed to collect the 24-hour urinary samples ade-
quately or had a decreased creatinine clearance
below 60 mL/min. Therefore, a total of 71 subjects
(type 1 diabetes in 11 patients, type 2 diabetes in
60 patients) participated in this study. We defined
type 1 diabetes patients as those whose fasting
C-peptide is less than 0.01 ng/dL (0.003 nmol/L)
and their serum responses to anti-glutamic acid
decarboxylase antibodies are positive. The control
subjects do not have hypertension or a history of
hyperglycemia, and their fasting glucose levels
should be below 110 mg/dL (6.1 mmol/L). They
have less than 5.8% glycated HbA1c and no first
relative with diabetes mellitus. They were selected
based on visits to the health examination promo-
tion center at Gyeongsang National University
Hospital between April and September 2002. Pro-
tocols were approved by the National University
of Gyeongsang Institutional Review Board and in-
formed consent was obtained from every subject.
The trial was conducted in accordance with the
Helsinki Declaration.
10 We analyzed the clinical
features between the type 2 diabetes (or type 1)
and control group (Table 1). There was no statis-
tical difference for age, sex ratio, body weight,
height, body mass index, alcohol drinking history,
smoking history or 24-hour urinary creatinine
amounts. Only the creatinine clearance was signi-
ficantly decreased in the type 2 diabetes group
compared to the control group. The statistical dif-
ference of age, body weight, height, alcohol-drin-
king history, smoking history and 24-hour uri-
Fig. 1. Chemical structures of chiro-inositol and myo-
inositol. The myo-inositol is epimerized at the carbon 1
position to form chiro-inositol.Tae-Sik Jung, et al.
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nary creatinine amounts between the type 1 group
and the control group was not significantly
different. The type 1 diabetes group was younger
than the control group. However, the body mass
index and creatinine clearance was higher in the
control group than in the type 1 diabetes group.
Compared to type 1 and type 2 diabetes groups,
the statistical values for age, height, alcohol
drinking history, smoking history, family history
of diabetes, duration of diabetes, 24-hour urinary
creatinine amounts and creatinine clearance were
acceptable. Also, the severity markers of diabetes
including diabetic neuropathy, diabetic retino-
pathy, HbA1c, and 24-hour urine proteinuria
showed no statistical difference. The type 1 dia-
betes group was younger as well as having a lower
body weight than the type 2 diabetes group. The
body mass index of the type 1 diabetes group was
lower than the type 2 diabetes group.
Collection and preparation of blood and urine
samples
Blood samples were collected at 8 a.m. after
fasting overnight, and serums were quickly sepa-
rated. Twenty-four-hour urinary samples were
collected from subjects who had regular diets.
Diabetes patients taking medications such as sul-
fonylureas, antihypertensive medicines, antilipide-
mic agents, and aspirins were not restricted. All
serum and urinary samples were immediately
stored at -40 .
Measurement of the concentration of
myo-inositol and chiro-inositol in 24-hour urine
samples
Myo-inositols and chiro-inositols in 24-hour uri-
nary samples were determined by a Dionex Bio
LC GP 50 Gradient Pump system (Dionex Corp.
01020506, Austin, TX, USA). Urine specimens
were analyzed with Dionex Carbopak MA-1 col-
umns (Dionex Corp. P/N 053699-01, Austin, TX,
USA) maintained at 50 by columns-heater. All
samples were then quantified by a Dionex ED 50
electrochemical Detector (Dionex Corp. 00120946,
Austin, TX, USA). Urine samples were filtered by
0.2μm Costar Spin-X membranes (Corning Incor-
Table 1. Comparison of Clinical Parameters of Subjects
Parameters
Type 1 diabetes
(N=11)
Type 2 diabetes
(N=60)
Control group
(N=39)
Statistical analysis
A B C
Age (yrs) 32.0 ± 10.5 53.0 ± 11.2 50.3 ± 5.5 NS
Sex (M/F) 6/5 29/31 19/20 NS NS NS
Weight (kg) 56.3 ± 15.1 64.1 ± 10.6 64.2 ± 10.6 NS NS
Height (cm) 164.5 ± 7.9 162.7 ± 7.8 163.4 ± 7.6 NS NS NS
BMI (kg/m
2) 20.6 ± 4.0 24.2 ± 3.2 23.9 ± 2.4 NS
Alcohol 0% (N=0) 8% (N=5) 10% (N=4) NS NS NS
Smoking 18% (N=2) 28% (N=17) 21% (N=8) NS NS NS
Urine Cr (mg/day) 906.4 ± 280.9 932.6 ± 226.6 1041 ± 343.1 NS NS NS
CCr (mL/kg/min) 77.1 ± 11.0 72.1 ± 10.2 83.7 ± 20.5 NS
Urine protein (mg/day) 119.4 ± 179.1 683.7 ± 1717.9 - NS
HbA1c (%) 10.7 ± 3.3 7.9 ± 2.1 5.0 ± 2.1 NS
DM duration (yrs) 2.8 ± 3.2 7.5 ± 6.6 0 NS
Family history of DM 18% (N=2) 20% (N=12) 0% (N=0) NS
DM neuropathy 9% (N=1) 33% (N=20) 0% (N=0) NS
DM retinopathy 18% (N=2) 32% (N=19) 0% (N=0) NS
NS, p>0.05, p<0.05, p<0.01.
Statistical significance between type 1 and type 2 diabetes (A), between type 1 diabetes and controls (B), between type 2 diabetes and
controls (C).Determination of Urinary Myo-/Chiro-Inositol Ratios from Korean Diabetes Patients
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porated Costar, 8161, Corning, NY, USA). Buff-
ered solutions of 60 mmol Sodium Hydroxide and
ion-free distilled water were used as catalysts, and
urinary components were eluted for one hour at
the speed of 0.4 mL/minute. Myo-inositols and
chiro-inositols were mixed at the density of 0.018
mg/mL each and 25μL of them were injected to
be used as experimental standards. Chromato-
grams were recorded by a DS chrom 99 chromato-
gram Data System (Donam Instrument, DS2000,
Seoul, South Korea) and under this condition,
myo-inositols showed a retention time of about 8
minutes, and chiro-inositols one of about 10
minutes. The concentration of myo-inositols and
chiro-inositols in specimens were determined from
comparison with standard materials.
Statistical analysis
All data were expressed as means±standard
deviation. We performed statistical analyses with
the Kruskal-Wallis method, and used independent
Student's t-tests for independent samples. P
values of less than 0.05 were considered to be
statistically significant.
RESULTS
The metabolic level of myo-inositols or chiro-
inositols in our body is an important indicator
to determine insulin resistance. From the three
experimental groups - type 1 diabetes, type 2
diabetes, and the control group - we determined
the level of myo-inositols and chiro-inositols in
24-hour urinary samples (Table 2). The amount
of 24-hour urinary myo-inositols in both type 1
diabetes and type 2 diabetes groups was about
three-fold higher than in the control group. On
the contrary, the amount of 24-hour urinary
chiro-inositols in type 1 diabetes was lower than
that in the control group, but the value was not
statistically significant. The type 2 diabetes
group revealed more severe decreases of 24-
hour urinary chiro-inositol level than the results
from the type 1 diabetes group. From these
values, we determined the myo-/chiro-inositol
ratio among three experimental groups (Table 2).
The ratio in type 1 and type 2 diabetes was
four- and six-fold higher than that in control
group, respectively, suggesting that diabetes
causes a decrease of chiro-inositol production
due to a defect of insulin action.
Furthermore, we compared the absolute a-
mounts of myo-inositol and chiro-inositol and their
ratio between type 1 and type 2 diabetes (Table
2). The amount of myo-inositols was not statisti-
cally different between the two diabetic groups
(665.5 ± 278.6 vs. 601.5 ± 299.1 mol/day, μ p=0.32).
The chiro-inositols amount in the 24-hour urine of
the type 1 diabetes group was higher than that of
type 2 diabetes group (65.5 ± 23.0 vs. 46.1 ± 26.0,
p=0.02). As a result, the myo-/chiro- inositol ratio
of the type 1 diabetes group was lower than that
of the type 2 diabetes group (10.3 ± 3.2 vs 17.3 ±
14.3) although its statistical significance was not
acceptable (p=0.09).
DISCUSSION
In this study we investigated the levels of myo-
inositol and chiro-inositol in 24-hour urine of
Korean diabetes patients to study their clinical
significance. The myo-/chiro-inositol ratio in the
type 2 diabetes group and the type 1 diabetes
Table 2. Statistical Comparison of 24-hour Urinary Myo- or Chiro-Inositol in Diabetes
Inositols Type 1 diabetes (N=11) Type 2 diabetes (N=60) Control (N=39)
Statistical analysis
A B C
Myo-inositols (μM/day) 665.5 ± 278.6 601.5 ± 299.1 193.3 ± 60.7 NS
Chiro-inositols (μM/day) 65.5 ± 23.0 46.1 ± 26.0 78.5 ± 31.7 NS
Myo-/chiro-inositol ratio 10.3 ± 3.2 17.3 ± 14.3 2.7 ± 0.9 NS
NS, p>0.05; p<0.05; p<0.01.
Statistical significance between type 1 and type 2 diabetes (A), between type 1 diabetes and controls (B), between type 2 diabetes and
controls (C).Tae-Sik Jung, et al.
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group was increased more than that in the control
group. Therefore, it is likely that the elevated
myo-/chiro-inositol ratio is associated with dia-
betes in this study.
The total amount of 24-hour urinary myo-inosi-
tols and chiro-inositols of the Korean type 2 dia-
betes group are higher than those of the American
and Japanese type 2 diabetic groups (Table 3).
9,11
However, the myo-/chiro-inositol ratio (17.3) is
similar to those from the American (20.4) and
Japanese studies (15.5). Also, the myo-/chiro-inosi-
tol ratios are significantly elevated in the type 2
diabetes group rather than in the control group in
all studies, indicating that the high myo-/chiro-
inositol ratio is closely related to type 2 diabetes.
The total amount of 24-hour urinary myo-inositols
in the Korean type 1 diabetes group are higher
than that in the American type 1 diabetes group.
The 24-hour urinary chiro-inositol level of Korean
type 1 diabetes group is higher than that of
American type 1 diabetes group (Table 3). But the
myo-/chiro-inositol ratios were not statistically dif-
ferent between the Korean type 1 diabetes group
and the American type 1 diabetes group (10.3 ±
3.2 vs 13.6 ± 4.1). Compared to each of the normal
control groups, the level of 24-hour urinary myo-
inositols and chiro-inositols in the Korean group
were similar to the levels in the Japanese group
but were much higher than the American control
group (Table 3). Nevertheless, the myo-/chiro-ino-
sitol ratio was similar among the Korean, Japanese
and American groups (2.7 ± 0.9 vs. 2.5 vs. 2.5).
The low level of chiro-inositol in diabetes could
be due to defect of conversion from myo-inositol
to chiro-inositol, but it was not affected by race,
country, eating habits, etc. The body inositol com-
ponents might be affected by dietary habits
because all studies did not restrict dietary foods,
and the Korean and Japanese generally consume
more inositol-rich foods such as soybean, brown
rice and barley than Americans do. However, it is
unlikely that dietary habits have an effect on the
body ratio of myo-/chiro-inositol among races.
Two types of chiro-inositols exist in the body.
One is chiro-inositol metabolically converted from
myo-inositol, and the other one is a pinitol (meth-
ylated D-chiro-inositol derivative) that is obtained
from dietary foods.
12 Myo-inositols are exclu-
sively converted into chiro-inositols in the inositol
phospholipids forms.
13 In the study which ra-
dioisotope tagged myo-inositols are injected into
peritoneum, myo-inositols are largely converted
to chiro-inositols in insulin sensitive tissues.
7
However, Goto-Kakizaki diabetic rats showed a
low conversion rate from myo-inositols into chiro-
inositols in insulin sensitive tissues. In contrast,
inositol phospholipids in Goto-Kakizaki diabetic
rats were highly elevated rather than in non-dia-
betic Wistar rats.
14
According to previous reports, insulin re-
Table 3. Comparison of 24-Hour Urinary Inositols among Korean, Japanese and American Groups
Korean Japanese American
Control group (N=39) (N=10) (N=44)
Myo-inositol ( mol/day) μ
Chiro-inositol ( mol/day) μ
Myo-/chiro-inositol
193.3 ± 60.7
78.5 ± 31.7
2.7 ± 0.9
192 ± 54
96.0 ± 17.6
2.5
91 ± 11
36.1 ± 6.6
2.5
Type 1 diabetes (N=11) (N=35)
Myo-inositol ( mol/day) μ
Chiro-inositol ( mol/day) μ
Myo-/chiro-inositol
665.5 ± 278.6
65.5 ± 23.0
10.3 ± 3.2
251 ± 32
18.5 ± 5.7
13.6 ± 4.1
Type 2 diabetes (N=39) (N=18) (N=50)
Myo-inositol ( mol/day) μ
Chiro-inositol ( mol/day) μ
Myo-/chiro-inositol
601.5 ± 299.1
46.1 ± 26.0
17.3 ± 14.3
499 ± 112
32.3 ± 16
15.5
270 ± 55
13.2 ± 3.6
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sistance and chiro-inositol deficiency were cor-
related in both Rhesus monkeys and humans.
6,11
Streptozotocin-induced diabetic rats injected intra-
muscularly by chiro-inositols showed a decrease of
plasma glucose levels and no hypoglycemia.
Therefore, chiro-inositols might play a role as
insulin sensitizers rather than as a direct mediator
in the insulin action. The pinitol-mediated hypo-
glycemia was inhibited by a phosphatidylinositol
3-kinase inhibitor, LY294002, in streptozotocin-
induced diabetic rats, suggesting that pinitol
might improve the phosphatidylinositol 3-kinase's
activity that is required for the translocation of
glucose transporter (GLUT4) to the cell membrane
in insulin sensitive tissues.
15
Insulin resistance might play a more important
role in the development of type 2 diabetes than
in type 1 diabetes. In fact, this study showed that
type 2 diabetes patients had a more significant
decrease of 24-hour urinary chiro-inositols and the
myo-/chiro-inositol ratio than patients with type 1
diabetes. This study has two drawbacks. First, all
subjects were not on controlled diets, so dietary
pinitols might influence the inositol level in urine
samples. Secondly, we did not determine insulin
resistance of each person in this study. However
it has been suggested that the myo-/chiro-inositol
ratio is closely related to insulin resistance ac-
cording to many other studies.
5,6,9,11
Nestler et al.
16 showed that insulin resistance is
a main pathogenetic cause of polycystic ovary
syndrome. In this study, nineteen patients showed
their improvement in insulin resistance and suc-
cessful ovulation (19/22, 86%) after oral medica-
tion with chiro-inositols. Moreover, two other in-
sulin-sensitizers, thiazolidinedione or metformin,
also affected ovulation by improving insulin resis-
tance.
17,18
In conclusion, we present that diabetes patients
have highly elevated myo-/chiro-inositol ratios
greater than the control group did, and the cor-
relation between its ratio and diabetes incidence
is statistically acceptable. However, its physiolo-
gical implication in the molecular mechanism of
diabetes is not clear. Therefore, we need to further
investigate how chiro-inositols or pinitols improve
insulin resistance and lower plasma glucose level
in type 1 and type 2 diabetes patients.
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